Key result
Protein kinase C beta (PKCbeta) inhibition suppressed insulin-mediated activation of hepatic SREBP-1c and its target lipogenic genes in mice.
PKCbeta is a key mediator of insulin-mediated activation of hepatic SREBP-1c, suggesting PKCbeta inhibition as a potential therapeutic target for diabetic complications.
Supports PKCβ inhibition in murine hepatic lipogenesis; hypothesis-generating for diabetic complications, with no clinical implications yet.
Sterol-regulatory element binding protein-1c (SREBP-1c) is a transcription factor that controls lipogenesis in the liver. Hepatic SREBP-1c is nutritionally regulated, and its sustained activation causes hepatic steatosis and insulin resistance. Although regulation of SREBP-1c is known to occur at the transcriptional level, the precise mechanism by which insulin signaling activates SREBP-1c promoter remains to be elucidated. Here we show that protein kinase C beta (PKCbeta) is a key mediator of insulin-mediated activation of hepatic SREBP-1c and its target lipogenic genes. Activation of SREBP-1c in the liver of refed mice was suppressed by either adenoviral RNAi-mediated knockdown or dietary administration of a specific inhibitor of protein kinase C beta. The effect of PKCbeta inhibition was cancelled in insulin depletion by streptozotocin (STZ) treatment of mice. Promoter analysis indicated that PKCbeta activates SREBP-1c promoter through replacement of Sp3 by Sp1 for binding to the GC box in the sterol regulatory element (SRE) complex, a key cis-element of SREBP-1c promoter. Knockdown of Sp proteins demonstrated that Sp3 and Sp1 play reciprocally negative and positive roles in nutritional regulation of SREBP-1c, respectively. This new understanding of PKCbeta involvement in nutritional regulation of SREBP-1c activation provides a new aspect of PKCbeta inhibition as a potential therapeutic target for diabetic complications.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2010) studied Hepatic steatosis and insulin resistance. PKCbeta inhibition (RNAi knockdown or specific inhibitor) was evaluated on Activation of SREBP-1c in the liver. Protein kinase C beta (PKCbeta) inhibition suppressed insulin-mediated activation of hepatic SREBP-1c and its target lipogenic genes in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: